Search for: "Robin Stillings" Results 61 - 80 of 1,867
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
20 Aug 2023, 6:07 pm
That at least is conceivable. still inconceivable is the possibility of  doing the same for civil society and foundations. [read post]
3 Aug 2023, 11:05 am by Rebecca Tushnet
Nonetheless there is still goodness in the world. [read post]
27 Jul 2023, 9:02 pm by News Desk
Professor Robin May, FSA chief scientific adviser, said: “Our risk assessment shows that there is still an ongoing risk to health associated with eating cold-smoked fish for specific groups of vulnerable people, including pregnant women and individuals with impaired immunity. [read post]
20 Jul 2023, 3:44 am by Rose Hughes
The approach of the UK courts to plausibility, on the other hand, still fits Sir Robin Jacob' characterisation of it as a humpty-dumpty-ish approach (i.e. the Humpty Dumpty of Lewis Carroll's Alice through the looking glass, for whom words have flexible meanings: "'When I use a word', Humpty Dumpty said in rather a scornful tone, 'it means just what I choose it to mean.'"). [read post]
12 Jul 2023, 3:57 am by Matrix Law
On appeal from: Mrs Philipp: [2022] EWCA Civ 318 In 2018 Mrs Fiona Philipp and her husband, Dr Robin Philipp, fell victim to a fraud. [read post]
10 Jul 2023, 4:00 am by Marc Bhalla
While that is stated tongue in cheek, it is nonetheless interesting to consider the cycle, as many of the life hurdles presented circa 1991 still apply today. [read post]
30 Jun 2023, 10:41 am by Florian Mueller
At that point, too, there is no reasonable likelihood of success, and even if the court went beyond that and balanced the equities, the FTC could still lose at that stage of the analysis. [read post]
28 Jun 2023, 5:32 am by John Coyle
Her invocation of “waiver” rather than “consent” was clearly purposeful (and a distinction that Robin Effron and John Coyle have recently explored). [read post]
24 Jun 2023, 12:20 pm by Florian Mueller
From a policy point of view, reasonable arguments can be made about whether trillion-dollar corporations that still have very significant organic growth rates should additionally be allowed to accelerate their growth by spending billions or, like in this case, tens of billions on acquisitions. [read post]
20 Jun 2023, 8:03 pm by The Dear Rich Staff
But the book is also not in Google Books or Gutenberg, which leads me to believe it's still under US copyright. [read post]
10 Jun 2023, 4:02 pm by Henry P Yang
Would finding the molecules that work still be undue burden? [read post]
9 Jun 2023, 9:16 am by Eleonora Rosati
After that, he discussed changes in the: court system; judiciary, both full-time and part-time; procedure and practice; alternative dispute resolution; court technology; and IP litigation itself.Lord Justice Arnold also focused on the topic of diversity in the IP profession, specifically the judiciary, He noted how the full-time IP judiciary in England and Wales still lacks in diversity. [read post]
9 Jun 2023, 9:07 am by Bill Marler
, Stx1, Stx2, Stx2c), and acts like the plant toxin ricin by inhibiting protein synthesis in endothelial and other cells. [16]   Endothelial cells line the interior surface of blood vessels and are known to be extremely sensitive to E. coliO157:H7, which is cytotoxigenic to these cells. [16] In addition to Shiga toxin, E. coli O157:H7 produces numerous other putative virulence factors, including proteins which aid in the attachment and colonization of the… [read post]
9 Jun 2023, 8:36 am by Ashwin Varma
The best of these studies is an ongoing one from Kate Ho & Robin Lee, who directly estimate that moving a branded drug from a preferred to non-preferred tier drops the expected market share of that drug for the given PBM by roughly 10%, and that these numbers are consistent with the observed rebates in the industry. [read post]
9 Jun 2023, 8:36 am by Ashwin Varma
The best of these studies is an ongoing one from Kate Ho & Robin Lee, who directly estimate that moving a branded drug from a preferred to non-preferred tier drops the expected market share of that drug for the given PBM by roughly 10%, and that these numbers are consistent with the observed rebates in the industry. [read post]